Biotech - Cell Therapy
•103 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (103)
%
| Company | Market Cap | Price |
|---|---|---|
|
Cell therapy platform with CAR-T and related cell-based therapies (e.g., CARVYKTI) directly produced and sold.
|
$458.89B |
$190.72
-0.67%
|
|
Gilead 직접 보유 자회사를 통해 CAR-T and cell therapy platforms (Yescarta, Tecartus, Anito-cel) 경로를 보유하고 있음.
|
$145.76B |
$117.18
-0.40%
|
|
VX-880 Zimislecel is an allogeneic stem cell-derived therapy, categorizing Vertex in the cell therapy space.
|
$104.72B |
$407.79
-1.34%
|
|
Breyanzi and Abecma are cell therapies, key assets in BMY's growth platform.
|
$89.46B |
$43.96
-1.83%
|
|
Biotech - Cell Therapy captures Bio-Techne's support of cell-based therapies and related platform tools.
|
$8.72B |
$55.63
+6.51%
|
|
CAR-T cell therapy programs CTX112/CTX131 are autologous/allogeneic cell therapies (cell therapy).
|
$6.31B |
$73.07
-5.51%
|
|
Core commercial product: BCMA-directed autologous CAR-T cell therapy (CARVYKTI) and the company's cell therapy platform.
|
$5.82B |
$31.70
-1.22%
|
|
azer-cel is an allogeneic CD19 CAR T-cell therapy in TG's pipeline, placing the company in the cell therapy space.
|
$5.36B |
$33.76
-3.16%
|
|
Directly develops cell therapies (CAR-T) and related platforms (ddCAR, ARC-SparX), which are Arcellx's core product offerings.
|
$4.52B |
$82.10
+3.69%
|
|
Directly develops and commercializes allogeneic mesenchymal stromal cell therapies (RYONCIL and rexlemestrocel-L).
|
$2.72B |
$2.12
|
|
BEAM-101 is an autologous ex vivo cell therapy using edited hematopoietic stem cells, placing Beam in the cell therapy category.
|
$2.65B |
$26.32
-7.58%
|
|
Pipeline includes NK cell therapies (t-haNK, M-ceNK) representing cell therapy modality.
|
$2.40B |
$2.54
+0.20%
|
|
Galapagos is pivoting to and actively developing cell therapies (CAR-T) for oncology, which is the core product focus.
|
$2.25B |
$34.10
+0.86%
|
|
Direct product category: Mesoblast's core offering is allogeneic mesenchymal lineage cell therapies (Ryoncil, rexlemestrocel-L, Revascor), which fit 'Biotech - Cell Therapy'.
|
$2.11B |
$18.32
-4.03%
|
|
Immune Medicine segment includes cell-therapy research and development programs (cell therapies).
|
$2.03B |
$13.36
-3.68%
|
|
Vericel's core products are autologous cell therapies (MACI, Epicel) and related biologic offerings, making 'Biotech - Cell Therapy' a direct representation of their primary manufacturing focus.
|
$1.60B |
$31.85
-3.51%
|
|
Core platform includes TCR-engineered autologous/allogeneic cell therapies (ACT), i.e., Biotech - Cell Therapy.
|
$1.07B |
$10.36
-5.39%
|
|
UltraCAR-T is an autologous cell therapy platform, aligning with Biotech - Cell Therapy.
|
$959.34M |
$3.25
-3.85%
|
|
Core product is an autologous cell therapy (rilparencel) targeting kidney disease, directly aligning with Cell Therapy as a primary business line.
|
$883.96M |
$3.02
-8.48%
|
|
Directly develops HIP-modified cell therapies (SC451) and other ex vivo engineered cell products, the core business line.
|
$753.35M |
$3.34
-1.47%
|
|
Engages in cell therapy development via Prime Edited CAR-T partnerships, aligning with autologous/allogeneic cell therapies.
|
$745.75M |
$5.68
-9.55%
|
|
Amtagvi lifileucel is an autologous tumor-infiltrating lymphocyte (TIL) cell therapy, the company's core product.
|
$737.99M |
$2.25
+2.04%
|
|
NeoCart regenerative medicine program represents cell therapy offerings.
|
$516.90M |
$1.79
+1.41%
|
|
The company markets living cell therapies (Apligraf, Dermagraft) which are aligned with the cell therapy biotech category.
|
$502.34M |
$3.96
-2.46%
|
|
Core product is autologous cell therapy (obe-cel CAR-T) categorized under cell therapy.
|
$441.79M |
$1.66
-6.21%
|
|
Velinotamig is a BCMAxCD3 bispecific T-cell engager asset; while not a traditional cell therapy, it represents a bispecific T-cell engager modality often associated with cell-therapy/immune-engager approaches.
|
$436.71M |
$7.40
+4.23%
|
|
Lineage's lead programs OpRegen, OPC1, and ReSonance ANP1 are allogeneic cell therapies, making Biotech - Cell Therapy the core direct product focus.
|
$385.92M |
$1.69
-1.74%
|
|
NWBO's DCVax platform products are autologous dendritic cell therapies, i.e., a cell therapy business line.
|
$358.65M |
$0.25
+2.66%
|
|
Ex vivo lentiviral cell-modified therapies constitute cell therapy via autologous gene-modified cells.
|
$351.23M |
$3.27
+0.46%
|
|
Capricor's lead asset, deramiocel, is a cell-based therapy developed from cardiosphere-derived cells aimed at treating DMD cardiomyopathy.
|
$324.07M |
$7.09
-6.96%
|
|
Direct cell therapy product category; off-the-shelf allogeneic CAR-T (UCART22/UCART20x22).
|
$291.26M |
$4.04
-3.81%
|
|
KYV-101 is an autologous CD19 CAR T-cell therapy, the core product line for Kyverna.
|
$286.54M |
$6.63
-5.69%
|
|
ZEVASKYN is an autologous cell-based therapy, aligning with the Cell Therapy investable theme.
|
$273.18M |
$5.34
-1.11%
|
|
Allogene's primary products are off-the-shelf allogeneic CAR T cell therapies (cell therapy).
|
$269.04M |
$1.23
-14.58%
|
|
Lyell's core direct product is LYL314, a CAR-T cell therapy (cell therapy) targeting cancer, which directly aligns with Biotech - Cell Therapy.
|
$262.11M |
$17.75
+11.99%
|
|
BioVascular Pancreas (BVP) is a cell-based therapy program (islet-related) in preclinical/early development, aligning with Biotech - Cell Therapy.
|
$241.99M |
$1.56
-4.29%
|
|
Directly develops autologous mRNA CAR-T cell therapy (Descartes-08) for autoimmune diseases.
|
$241.89M |
$9.32
-8.09%
|
|
Lead programs trem-cel and trem-cel+VCAR33 are cell therapies using engineered hematopoietic stem cells.
|
$234.05M |
$37.46
+1.57%
|
|
Directly develops and sells cell therapies (CAR-T) using a gene editing platform, i.e., Biotech - Cell Therapy.
|
$213.91M |
$2.30
+5.50%
|
|
CRGX directly developed autologous CAR T-cell therapies (firi-cel) and related cell-therapy programs (CRG-23), which are core, direct products.
|
$206.13M |
$4.47
|
|
TARA-2.00 is a cell therapy platform (OK-432) developed by Protara; a core product category is cell therapy.
|
$201.40M |
$5.22
-8.42%
|
|
Core business is building off-the-shelf cell therapies (CAR T and CAR NK) derived from iPSCs for multiple indications.
|
$187.42M |
$1.64
+0.31%
|
|
Biotech - Cell Therapy: cell therapy manufacturing and modification enabled by MaxCyte's platform.
|
$167.98M |
$1.66
+5.06%
|
|
Lead pipeline SER-155/SER-147 are cultivated live biotherapeutics, a cell-therapy modality.
|
$153.34M |
$18.77
-3.17%
|
|
Nkarta's lead candidate NKX019 is an allogeneic CAR NK-cell therapy, directly aligning with the Cell Therapy product category.
|
$151.14M |
$2.13
-2.29%
|
|
RECELL-based autologous cell suspension therapy aligns with Biotech - Cell Therapy as a core regenerative medicine product.
|
$140.50M |
$1.00
|
|
Directly develops cell therapy programs (CER-T CAR-T) for ovarian cancer, a primary product line.
|
$139.47M |
$4.33
-12.35%
|
|
RECELL is an autologous skin-cell suspension therapy, aligning with Biotech - Cell Therapy as a cell-based regenerative treatment.
|
$135.87M |
$5.14
-6.72%
|
|
Tevogen's core offering is off-the-shelf, precision T cell therapies using the ExacTcell platform, i.e., cell therapy products.
|
$131.50M |
$0.72
-3.36%
|
|
Company is advancing TCR-T cell therapies, a form of cell therapy for cancer.
|
$125.07M |
$2.21
+0.45%
|
|
Cabaletta's lead product rese-cel is a CD19-directed CAR T cell therapy, i.e., a cell therapy product in biotech.
|
$123.81M |
$2.44
-1.61%
|
|
GADLEN platform and gamma delta T cell–related preclinical programs indicate Cell Therapy activities.
|
$109.21M |
$2.28
+1.33%
|
|
Affini-T collaboration targets ex vivo gene-edited T-cell therapies, indicating a cell therapy focus.
|
$106.91M |
$2.86
-8.04%
|
|
EUDA is pivoting to stem-cell and regenerative medicine, including iPSC-based cell therapies, making Cell Therapy a core current product/technology focus.
|
$102.23M |
$2.86
+4.38%
|
|
COYA's autologous Treg cell therapy program (COYA 101) and exosome-based strategies place it in the cell therapy space.
|
$101.52M |
$6.07
-3.04%
|
|
Atara's lead program tab-cel (Ebvallo) is a allogeneic cell therapy, i.e., a cell-based immunotherapy.
|
$93.18M |
$15.09
-3.45%
|
|
Fortress owns cell therapy assets (Mustang Bio) as part of its diversified biotech portfolio.
|
$80.13M |
$2.71
-3.56%
|
|
Directly aligns with Adicet's core offering of allogeneic cell-based therapies (gamma delta T cell therapies) as the company focuses on cell therapy products.
|
$80.00M |
$0.97
+5.13%
|
|
The AIDE platform encapsulates drugs in autologous red blood cells, representing a cell-therapy–style delivery approach central to the company’s technology.
|
$75.02M |
$1.65
+0.61%
|
|
Directly develops NXC-201, a sterically-optimized CAR-T cell therapy, which is a cell therapy platform.
|
$69.69M |
$2.50
-7.41%
|
|
Directly develops AlloNK allogeneic NK cell therapy platform (AB-101) for autoimmune indications, a core cell therapy product.
|
$68.46M |
$2.81
-7.87%
|
|
Temferon is a hematopoietic stem cell gene therapy, a cell-based therapy approach.
|
$59.44M |
$3.25
-2.98%
|
|
MiNK Therapeutics' core business is the discovery, development, and manufacturing of allogeneic, off-the-shelf iNKT cell therapies (cell therapy platform).
|
$55.80M |
$14.00
-4.24%
|
|
GEAR Cell Therapy Platform and SNAP-CAR assets are direct cell therapy products within oncology.
|
$55.17M |
$15.70
-1.94%
|
|
Adaptimmune directly develops engineered T-cell therapies (TECELRA, lete-cel, uza-cel) using a cell therapy platform.
|
$49.11M |
$0.18
-9.80%
|
|
Core Celularity business centers on allogeneic placental-derived cell therapies marketed as off-the-shelf products.
|
$49.10M |
$2.05
-3.76%
|
|
Century Therapeutics directly develops iPSC-derived allogeneic cell therapies (CAR-iNK, iT cells) and related platforms.
|
$49.00M |
$0.57
-5.22%
|
|
INKmune is a cell therapy platform (NK cell therapy), a direct Biotech - Cell Therapy product.
|
$48.97M |
$2.08
-1.18%
|
|
Iomab-ACT represents cell-therapy conditioning, placing Actinium in the cell therapy enablement space.
|
$46.48M |
$1.49
-1.97%
|
|
Senti's lead program SENTI-202 is an off-the-shelf CAR-NK cell therapy, directly fitting Biotech - Cell Therapy.
|
$44.08M |
$1.69
-11.05%
|
|
Directly relates to cell therapy initiatives via cord blood stem cell sourcing and processing; CCEL's core business is cord blood banking and tissue storage, which aligns with cell therapy ecosystems.
|
$35.77M |
$4.43
+0.35%
|
|
Direct placenta-derived cell therapy and MAIT-cell immunotherapy pipelines powering Pluri's core business.
|
$34.35M |
$4.39
-2.55%
|
|
Allocetra is Enlivex's lead product, a macrophage-reprogramming cell therapy, directly fitting the 'Cell Therapy' category.
|
$25.29M |
$1.15
-1.71%
|
|
Biotech cell therapy-oriented tissue regeneration using rhCollagen scaffolds.
|
$25.20M |
$2.20
-6.38%
|
|
The company’s core platforms are cell-based therapies (gamma delta T cells and cord blood-derived NK cells) used to treat cancer and autoimmune diseases.
|
$23.77M |
$2.06
-8.44%
|
|
FibroBiologics' core business is fibroblast-based cell therapy with lead candidates CYWC628, CYMS101, and CybroCell, fitting the Biotech - Cell Therapy category.
|
$21.01M |
$0.55
-0.05%
|
|
Pipeline includes cell therapy assets (e.g., KROS 201 uses dendritic cells).
|
$19.55M |
$1.16
-12.12%
|
|
Precise PRP licensing indicates involvement in cell-based regenerative therapies for animals.
|
$18.52M |
$1.28
+1.35%
|
|
Biotech - Cell Therapy aligns with cell-based therapeutic modalities that Fuse Biotech could pursue.
|
$15.41M |
$0.24
|
|
NoveCite is a stem cell therapy program (cell therapy), representing a direct biotech product line.
|
$12.66M |
$1.23
-6.11%
|
|
Longeveron's lead candidate laromestrocel is a mesenchymal stem cell (MSC) based cell therapy.
|
$12.20M |
$0.81
-7.66%
|
|
Directly manufactures autologous stem cell therapy (BRTX-100) for chronic lumbar disc disease, a core cell therapy product line.
|
$12.16M |
$1.62
-5.81%
|
|
Core product platform MAR-T cell therapy (multi-antigen T-cell therapy) for cancer.
|
$11.43M |
$1.01
-4.72%
|
|
Core business is cell therapy with engineered macrophages; CAR-M platform qualifies as a cell-based therapy.
|
$10.90M |
$0.24
-6.09%
|
|
PHIO pursues adoptive cell therapy (ACT) approaches, including NK cells and TIL-based strategies, aligning with Biotech - Cell Therapy.
|
$10.57M |
$2.20
-7.09%
|
|
Motixafortide mobilizes stem cells, a core enabler for cell therapy pipelines.
|
$9.38M |
$3.91
-5.10%
|
|
CELZ's ImmCelz and AlloStem platforms are core cell-therapy products/technologies the company develops and advances.
|
$8.61M |
$3.33
-4.31%
|
|
Active involvement in cell therapy and regenerative medicine through a joint venture in China.
|
$8.46M |
$0.00
-20.00%
|
|
Directly developing cell therapy products (Selected TILs) for solid tumors.
|
$8.21M |
$0.35
|
|
Core business: BioCardia's lead programs CardiAMP and CardiALLO are autologous/allogeneic cell therapies.
|
$7.04M |
$1.36
+0.37%
|
|
Core focus on CAR T and cell-based therapies (MB-101, MB-109) and oncolytic virus programs, i.e., cell therapy.
|
$6.92M |
$1.56
-0.95%
|
|
The company's platform centers on cell therapy, encapsulated live cells that deliver targeted prodrug activation for cancer treatment.
|
$6.86M |
$1.00
|
|
IN8bio's core program is gamma-delta T cell therapy (INB-100/INB-200) and related iPSC-derived gamma-delta T cell products, i.e., cell therapy.
|
$6.35M |
$2.10
-7.08%
|
|
ALZN002 uses autologous dendritic cells as a cell-based vaccine, fitting Biotech - Cell Therapy.
|
$6.31M |
$2.18
-5.63%
|
|
HCWB's lead programs include CAR-T and T-cell engager approaches, which are core cell therapy modalities.
|
$5.84M |
$4.06
-10.77%
|
|
ERNA's core platform is iPSC-derived mesenchymal stem cells (iMSCs) used as off-the-shelf therapies; aligns with Biotech - Cell Therapy.
|
$5.38M |
$1.29
-5.47%
|
|
Bria-IMT and Bria-OTS are cell-based therapies (off-the-shelf/allogeneic and personalized) in development.
|
$4.69M |
$12.40
-2.21%
|
|
NurOwn is a proprietary autologous cell therapy platform (bone marrow–derived mesenchymal stem cells induced to secrete neurotrophic factors) that is the core product being developed for ALS.
|
$4.53M |
$0.69
-2.13%
|
|
NeuroNova and SuperNova utilize stem cell-embedded viral platforms, representing cell therapy delivery within oncology.
|
$4.11M |
$1.55
-1.90%
|
|
Core focus on endometrial stem cell research and cell-based therapies (cell therapy).
|
$2.32M |
$0.01
|
Showing page 1 of 2 (103 total stocks)
Loading industry metrics...
Loading comparison data...
